Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?
Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on the current and potential impact of the D…
S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord
Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on vaccine confusion (taking the flu vaccine,…
S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries
Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses on the case for post-jab immunologic testing f…
S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses
Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses on the process of moving immunocompromised and …
S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH
Donna Cryer joins the Surfers to discuss the different effects that the Delta Variant of COVID-19 is having on different stakeholders within the Fatty Liver community.
What impact is the…
S2-E43.4 -Rethinking Cirrhosis: A Call To Action
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfers and our listeners.
In terms of cirrhosis and…
S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change in perspective.
Once we accept the idea that cirr…
S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target than F2/3.
This conversation focuses on specifi…
S2-E43.1 - Cirrhosis - Challenges in Treating Patients
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treating NASH cirrhosis.
This conversation focuses on …
S2-E43 - Can Cirrhosis Drive Drug Development In NASH?
Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis, which evolves into a discussion about how to drive NITs forward.
Historically, NASH drug development strateg…
S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates
Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. T…
S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH
Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. T…
S2-E42.1 - FGF drugs in Development - A Promising Class of Agents
Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. T…
S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?
Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy.
Th…
S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value
Co-authors Ken Cusi and Stephen Harrison discuss reasons to be optimistic and activist about the multidisciplinary call to action regarding the coming NASH Epidemic while NASH kNOWledge…
S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH
Co-authors Ken Cusi and Stephen Harrison discuss critical success factors in the multidisciplinary call to action regarding the coming NASH Epidemic while NASH kNOWledge President Antho…
S2-E41.2 - Specialties and Organizations Unite to Fight the NASH Epidemic
Co-authors Ken Cusi and Stephen Harrison discuss how the multidisciplinary call to action regarding the coming NASH Epidemic came to be, while NASH kNOWledge President Anthony Villiotti…
S2-E41.1 - SPECIAL FEATURE: Interview with Louise Campbell
Roger Green and Louise Campbell discuss some of the key elements of the "Preparing for the NASH Epidemic - a Call to Action" paper itself along with the discussion during Surfing NASH E…
S2-E41 - Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action
Co-authors Ken Cusi and Stephen Harrison discuss the multidisciplinary call to action regarding the coming NASH Epidemic, how the first paper came to be and what lies behind it, while N…
S2-E40.3 - Discussing Comprehensive Care Models For NAFLD - Metrics, Key Performance Indicators and Improving Management
Jeff Lazarus and Roger Green discuss the ease of creating valuable metrics in a comprehensive care model, while our three practitioners -- Stephen Harrison, Jörn Schattenberg and Louise…